Lek assists Pediatric Clinic in move to the new buidling

29. 6. 2009

On Saturday, June 27, the Pediatric Clinic in Ljubljana moved to the new building on Bohoričeva Street. Lek, a Sandoz company, assisted in this difficult and extensive process, which involved moving all of the medical equipment, as well as a huge amount of documents and archives from all of the Pediatric Clinic’s departments.

According to Marinka Purkart, Chief Nursing Officer at the Pediatric Clinic the most difficult part was moving the dialysis equipment, since it is extremely heavy and awkward to move. A great deal of effort was also required to move the documents and equipment from the location on Stara Pravda Street, which has no elevators. Therefore they are very thankful for Lek’s significant contribution, which made the full day of work moving to the new facilities faster and easier.

“Along with the rest of Slovenia, we at Lek, a Sandoz company, were very happy to hear that the new Pediatric Clinic would be opening soon, so we were glad to help them and, we hope, make the move at least a little easier. We hope that we helped the young patients to start getting better as soon as possible in the new and modern facilities,” said Lek Head of Corporate Communications Katarina Klemenc Dinjaški.

* * *

Lek, a Sandoz company, is one of the pillars of leading world generics company Sandoz. It operates as a global development center for products and technologies, as a global manufacturing center for active pharmaceutical ingredients and medicines, as a competence center for the development of vertically integrated products, as a Sandoz competence center in the field of development and manufacturing of biosimilar products and as a supply center for the markets of CEE, SEE and CIS, sales Slovenia and sales services for Sandoz global markets. For further information please visit http://www.lek.si/eng/

Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a portfolio of approximately 1000 compounds and sells its products in more than 130 countries. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these medicines along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany) and Eon Labs (US). In 2008, Sandoz employed around 23,000 people worldwide and posted sales of USD 7.6 billion. For further information please visit www.sandoz.com

Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group’s continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 96,700 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com

* * *

V sporočilu za javnost so izjave in napovedi o Lekovem poslovanju v prihodnje. Napovedi obsegajo ocene, oblikovane na podlagi vseh informacij, ki jih imamo trenutno na voljo. Če bi se izkazalo, da so predvidevanja teh napovedi nezanesljiva, bi bili lahko dejanski rezultati poslovanja drugačni od pričakovanih.

- end -

Za dodatne informacije se, prosim, obrnite na:

Katarino Klemenc Dinjaški

Korporativno komuniciranje

Lek farmacevtska družba d. d.

telefon: 01 580 22 43

telefaks: 01 580 24 32